Kluyveromyces B0399 and Intestinal microbiota in Covid-19 infected patients
Trial 252: Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial Vicente Navarro-L&oacGastric resistence and sattle in the intestine: Kluyveromyces B0399
Trial 138:Administration of a yogurt enriched with Kluyveromyces marxianus fragilis B0399 and Bifidobacterium l. BB12: a study on its impact on the intestinal microbiota of subjects with dysfunctionalGastric resistance and colonization of the intestinal tract
Trial 130.1: The ability of Kluyveromyces marxianus fragilis B0399 to pass through the gastric barrier and colonize the intestine - examination of human feces after oral uptake by healthy volunteers.Lactic yeast Kluyveromyces B0399 (Kluyver B0399) on patients suffering from irritable colon
Trial 16:The use of Saccaromyces cerevisiae and Kluyveromyces fragilis B0399 is recommended in all cases of intestinal dismicrobism induced by organic diseases and/or antibiotics, but also for putting